- Optimi Health (CSE: OPTI) has completed its harvest of psilocybe cubensis earmarked for export to Australia
- In preparation for the international export, the company harvested 300 kg of psilocybe cubensis mushrooms at its GMP manufacturing facility in Princeton, British Columbia
- The psilocybin extract from the latest harvest will be tested, analyzed, and validated by a third-party laboratory before it shipped to Australia
- Optimi Health Corp. (OPTI) opened trading at C$0.22 per share
Optimi Health (CSE: OPTI) has completed its harvest of psilocybe cubensis earmarked for export to Australia.
In preparation for the international export, the company harvested 300 kg of psilocybe cubensis mushrooms at its GMP manufacturing facility in Princeton, British Columbia.
The psilocybin extract from the latest harvest will be tested, analyzed, and validated by a third-party laboratory before it shipped to Australia. Once the analysis is complete, the product will be processed and encapsulated at the company’s facility in preparation for export, pending the appropriate permits.
The medical-grade GMP psilocybin will be extracted from the mushrooms, processed, and shipped to Australia, where it will be sold to other licensed entities in that medical market through Mind Medicine Australia and the company’s representatives.
“The evidence-based decision by the TGA to reschedule psilocybin and MDMA is a positive step for the future of mental health and a monumental undertaking in logistics,” said Optimi CEO, Bill Ciprick. “To be entrusted as the exclusive supplier to Mind Medicine Australia, the largest Australian trainer of psychedelic-assisted therapy practitioners, is both an honour and a tremendous responsibility. I am proud to say that thanks to our unmatched production capacity and with the support of our operations team, Optimi is excited to deliver on our international supply commitments in advance of the rescheduling date.”
The company committed to supply both its GMP medical-grade psilocybin extract and MDMA to Mind Medicine Australia in advance of the rescheduling of these substances on July 1, 2023.
Optimi Health Corp. (OPTI) is a drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP-grade psilocybin, synthetic psychedelic substances, and functional mushrooms that focus on the health and wellness markets.
Optimi Health Corp. (OPTI) opened trading at C$0.22 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.